Every 10-Q that Castle Biosciences, Inc. (CSTL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CSTL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CSTL filings page.
Castle Biosciences reported net revenues of $103.5 million for the three months ended June 30, 2026, up from $86.2 million a year earlier, driven by growth in non-dermatologic tests. Operating loss narrowed to $3.1 million and net loss was $2.1 million versus net income of $4.5 million in 2025.
For the first half of 2026, net revenues were $187.2 million compared with $174.2 million, while net loss improved to $16.6 million from $21.3 million. Total test reports rose to 57,755 from 50,976, led by TissueCypher (26,733 vs. 16,602) and DecisionDx‑Melanoma (20,301 vs. 18,602).
Cash and cash equivalents were $62.1 million and marketable investment securities $204.7 million at June 30, 2026; management expects these resources and anticipated revenues to cover at least the next 12 months. The company continues a limited launch of its AdvanceAD‑Tx test and is responding to an HHS OIG subpoena requesting historical billing information.
Castle Biosciences reported Q1 2026 results with net revenues of $83.7 million, down from $88.0 million a year earlier, as its dermatologic and gastroenterology diagnostics portfolio continued to drive sales. The company’s net loss narrowed to $14.5 million from $25.8 million, reflecting lower operating expenses, including a sharp reduction in amortization of acquired intangibles.
Cash and cash equivalents were $63.8 million and marketable investment securities were $197.9 million as of March 31, 2026, supporting management’s view that current resources and expected revenues can fund operations for at least the next 12 months. Test volume grew to 26,933 reports, driven by growth in DecisionDx-Melanoma and a 58% increase in TissueCypher usage, while operating cash outflows increased as the company invested in its expanding test portfolio and new facilities.
Castle Biosciences (CSTL) reported Q3 2025 results. Net revenues were $83.0 million versus $85.8 million a year ago, and the quarter showed a net loss of $0.5 million compared with net income of $2.3 million. For the nine months, net revenues reached $257.2 million, up from $245.8 million, while the company posted a net loss of $21.8 million versus income of $8.7 million last year.
Operating expenses rose on higher cost of sales and SG&A, and year‑to‑date amortization increased after the discontinuation of IDgenetix, which accelerated $20.1 million of expense. The balance sheet remained strong with cash and cash equivalents of $85.6 million and marketable investment securities of $202.0 million as of September 30, 2025. Year‑to‑date cash provided by operating activities was $37.4 million.
Dermatologic testing contributed $48.5 million and non‑dermatologic $34.5 million in Q3. The company closed an asset acquisition of Capsulomics (developed technology valued at $28.2 million) and entered a collaboration with SciBase. Long‑term debt stood at $10.0 million; the interest‑only period on the term loan was extended to December 1, 2026.